Clinical Trial Update: Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating immunogenicity and safety of a tetravalent dengue vaccine given with or after Cervarix, with completed status and results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever
• Dengue Hemorrhagic Fever

Drugs mentioned

• Cervarix (human papillomavirus vaccine, bivalent)
• Tetravalent dengue vaccine

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Status: COMPLETED | Results posted: 2020-03-09